

Press Release

Zug, 19 July 2011

HBM BioVentures sells mtm laboratories, the biggest private investment in the portfolio

- The sale of mtm increases HBM BioVentures' net asset value (NAV) by CHF 3.35 per share, or 5.8%, and doubles the book value of the mtm investment
- Upfront cash proceeds to HBM BioVentures of EUR 47 million (CHF 54 million)

HBM BioVentures announced today it will sell mtm laboratories to Roche (SIX: RO, ROG; OTCQX: RHHBY) for a total upfront payment of approximately EUR 130 million as well as up to approximately EUR 60 million upon reaching performance-related milestones, in cash. HBM BioVentures will receive upfront proceeds of EUR 47 million at closing of the transaction and after release of the escrow. These upfront proceeds and the rights to receive future performance-related milestones, conservatively valued, lead to an increase of the net asset value (NAV) by CHF 3.35 per share, or 5.8%. This represents an annualized return over the investment period of 19%. HBM BioVentures had invested EUR 24.3 million in mtm in four financing rounds between 2003 and 2010, and held a 33.3% equity stake. The closing of the transaction is expected in the coming weeks and is subject to customary closing conditions.

“The success of the development and sale of mtm laboratories illustrates once more the importance of working actively with companies in the portfolio. HBM representatives were intimately involved over many years in guiding mtm laboratories in the functions of chairman and vice-chairman. After the sale of Brahms in September 2009 this is the second successful trade sale of a diagnostics company by HBM BioVentures”, comments Dr. Andreas Wicki, CEO of HBM BioVentures.

mtm laboratories AG is an ISO 9001 and ISO 13485 certified developer and manufacturer of In-Vitro Diagnostic Devices (IVDD) for use in the early detection and diagnosis of cervical cancer. The Company operates on a global basis with headquarters in Heidelberg, Germany and subsidiaries in the United States, France, Italy and Spain. Further information can be found at: www.mtmlabs.com

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA



For further information, please contact Dr. Andreas Wicki, CEO HBM BioVentures Ltd, Tel. +41 41 768 11 08, andreas.wicki@hbmbioventures.com

About HBM BioVentures Ltd

HBM BioVentures is invested globally in some 25 mature companies in the biotechnology/ human medicine, diagnostics and medical technology sectors. The lead products of many companies in HBM BioVentures' portfolio are either at an advanced stage of development or already available on the market. The investment focus currently is on follow-on financings for private companies in the portfolio that offer high value-creation potential. HBM BioVentures is an interesting alternative to investments in big pharma and biotech companies. HBM BioVentures has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (Wertpapierprospektgesetz). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM BioVentures Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM BioVentures Ltd
Bundesplatz 1
CH-6300 Zug / Switzerland
Tel:+41 41 768 11 08
Fax:+41 41 768 11 09
info@hbmbioventures.com
www.hbmbioventures.com